Thermogenic stimulation with a β3-adrenergic receptor agonist prevents the cold- induced rise of phosphorylated tau in a mouse model of Alzheimer’s disease
Pharmacological activation of brown adipose tissue via a β3-adrenergic receptor agonist prevents cold-induced tau hyperphosphorylation and attenuates amyloid pathology in a mouse model of Alzheimer's disease, suggesting a potential therapeutic strategy that addresses both metabolic deficits and neuropathology.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Alzheimer's disease is a condition that slowly erodes memory and thinking, and it is most common in older adults. For decades, scientists have known that the aging brain struggles to regulate its own temperature, often becoming cooler than it should be. This drop in body heat is not just a side effect of getting older; it appears to be a trigger for the disease itself. When the brain gets too cold, a specific protein called tau, which normally helps support brain cells, begins to change shape. It becomes sticky and clumps together, forming the toxic tangles that are a hallmark of Alzheimer's. While we cannot easily keep an elderly person's brain at a perfect temperature around the clock, researchers are looking for ways to boost the body's natural ability to generate heat. The body has a special type of fat, known as brown fat, that acts like an internal furnace, burning energy to keep us warm. The question driving this new research was whether waking up this internal furnace could stop the brain from getting cold and, in turn, stop the toxic protein clumps from forming.
A team of researchers at Université Laval and the CHU de Québec-Université Laval set out to test this idea using a mouse model that naturally develops the brain changes seen in Alzheimer's. They focused on a specific chemical switch in the body called the beta-3 adrenergic receptor, which is found in high numbers in brown fat. When this switch is flipped, it tells the brown fat to start burning energy and producing heat. The scientists gave a medication that flips this switch to older male mice, both those with the Alzheimer's-like condition and healthy ones. They treated these mice for four weeks with daily injections of the drug, which is designed to activate the brown fat. After this month of treatment, they subjected the mice to a sudden, intense cold challenge, placing them in a room at 4 degrees Celsius for 24 hours. This cold exposure is a known stressor that typically causes the tau protein in the brain to become highly phosphorylated, a technical term for a chemical modification that makes the protein toxic and prone to clumping. The researchers compared these cold-exposed mice to a control group that stayed in a comfortable room temperature and did not receive the drug.
The results showed that the drug worked exactly as hoped to protect the brain. In the mice that received the medication, the internal furnace was active, and their bodies were better at generating heat. When these treated mice were exposed to the cold, their brains did not show the usual spike in toxic tau protein. In fact, the drug almost completely prevented the cold from causing the tau protein to become sticky and harmful in the hippocampus, the part of the brain responsible for memory. This protection was specific to the soluble form of the protein, which is the version that can spread and damage brain cells before it forms large, solid clumps. The healthy mice also benefited from the treatment, showing improved blood sugar control and weight loss, but the most striking finding was the preservation of the brain in the Alzheimer's mice. The drug essentially acted as a shield, allowing the mice to withstand the cold stress without suffering the brain damage that usually follows.
The study also looked at what was happening in the blood. The researchers found that when the mice were exposed to the cold, a specific form of the toxic tau protein, known as pTau-217, appeared in their bloodstream. This is significant because pTau-217 is a biomarker that doctors are beginning to use to detect Alzheimer's in living patients. In the mice that received the drug, the level of this toxic protein in the blood was much lower than in the untreated mice. This suggests that the drug not only protected the brain but also stopped the toxic protein from leaking out into the rest of the body. The researchers also observed that the drug helped maintain a healthy balance of amyloid-beta, another toxic protein involved in Alzheimer's, though the effect on this protein was less dramatic than the effect on tau.
While the findings are promising, the researchers are careful to note that this was a study in mice, and the way mice generate heat is different from how humans do. Mice have a much higher capacity for brown fat activity than people, especially older people. However, the study provides a clear proof of concept: by chemically activating the body's heat-generating system, it is possible to stop the cold-induced damage that leads to Alzheimer's pathology. The drug used in the study is a beta-3 adrenergic receptor agonist, a type of medication that has been tested in humans for other conditions like diabetes and obesity, though with mixed results so far. This new research suggests that the drug might have a different, and perhaps more powerful, role to play in protecting the aging brain. It offers a new perspective on Alzheimer's, suggesting that keeping the body warm, or at least helping the body generate its own heat, could be a viable strategy to slow down or prevent the toxic changes that cause memory loss. The work highlights a direct link between the body's ability to stay warm and the health of the brain, turning a simple physiological function into a potential key for unlocking new treatments.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.